g-Nostics Announces Award of Key Patent in Europe for Production of Patch Formulations of Generic Drugs
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
g-Nostics Ltd, the personalized medicine company, announces the award of a key patent for the production of patch formulations which g-Nostics will apply to the manufacturing of low cost generic drug patch formulations with their joint venture partner in Beijing for both the domestic Chinese market and for export to other markets.
The transdermal production patent which g-Nostics holds under exclusive license from Transdermal Technologies & Systems Ltd (Windsor, UK) will allow g-Nostics to capitalize on its position as a leader in the Companion Diagnostic (CDx) market in smoking cessation by bringing the treatment together with the diagnostic to optimize both cost and clinical effectiveness in one of the world's largest therapeutic markets.
The first CDx product is a range of patches delivering nicotine over both 16hrs and 24hrs and is bio-equivalent to standard 'low' doses found on 'Over the Counter' shelves across Europe and the USA up to 63mg/24hrs.
A full range of Nicotine Replacement Therapy (NRT) patches allows the proprietary NicoTest® diagnostic to identify optimum treatment and dosing regimes to ensure the healthcare professional can selectively prescribe treatment on an individual basis to maximize the prospect of a positive clinical outcome.
The patent has been granted in Europe and was published on 28th April 2010 in the EPO's official bulletin as patent no 1755954.
The transdermal production patent which g-Nostics holds under exclusive license from Transdermal Technologies & Systems Ltd (Windsor, UK) will allow g-Nostics to capitalize on its position as a leader in the Companion Diagnostic (CDx) market in smoking cessation by bringing the treatment together with the diagnostic to optimize both cost and clinical effectiveness in one of the world's largest therapeutic markets.
The first CDx product is a range of patches delivering nicotine over both 16hrs and 24hrs and is bio-equivalent to standard 'low' doses found on 'Over the Counter' shelves across Europe and the USA up to 63mg/24hrs.
A full range of Nicotine Replacement Therapy (NRT) patches allows the proprietary NicoTest® diagnostic to identify optimum treatment and dosing regimes to ensure the healthcare professional can selectively prescribe treatment on an individual basis to maximize the prospect of a positive clinical outcome.
The patent has been granted in Europe and was published on 28th April 2010 in the EPO's official bulletin as patent no 1755954.
